Search
isocitrate dehydrogenase-1 (IDH1) gene mutation
Indications:
- evaluation of gliomas
- eligibility for vorasidenib (FDA-approval pending)
- evaluation of acute myeloid leukemia (AML)
- eligibility for ivosidenib (FDA-approval pending)
Related
NADP isocitrate dehydrogenase 1 (isocitrate dehydrogenase [NADP] cytoplasmic, IDH1)
General
gene mutation testing; gene mutation analysis
References
- CPT
- Ingram I.
Ivosidenib Induces Deep Remissions in IDH1-Mutant AML
On strength of phase I data, drug appears headed for
FDA approval.
MedPage Today. June 03, 2018
https://www.medpagetoday.com/meetingcoverage/asco/73242
- DiNardo CD, Stein EM, de Botton S et al
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or
Refractory AML.
N Engl J Med. Jun 2, 2018
PMID: 29860938
https://www.nejm.org/doi/full/10.1056/NEJMoa1716984
- Pollyea DA, et al
Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory
acute myeloid leukemia (R/R AML): Results of a phase 1 study.
American Society of Clinical Oncology (ASCO) 2018;
Abstract 7000